The blockbuster GLP-1 drugs that have reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders — and reduce the tragic outcomes they cause, a large new study ...
Accumulating scientific evidence and industry interest from Eli Lilly, Altimmune and startup Baseline Therapeutics is driving further research on the therapeutic potential of GLP-1 receptor agonists ...
OSHKOSH, Wis. (WFRV) – ThedaCare and Apricity announced on Thursday that they would expand a significant program designed to ...
Global Impact Wellness launches in Baltimore, MD, offering mental health and substance use care focused on accessibility, ...